Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Asceneuron

Request full access

Develops effective therapeutics for orphan tauopathies

Lausanne, SwitzerlandFounded 2012Biotech & Life Sciences

About Asceneuron

Asceneuron is an emerging biotech company focused on discovering and developing groundbreaking therapeutics for neurodegenerative disorders, particularly those with high unmet medical needs such as orphan tauopathies and other related diseases. The company operates in the biotechnology and pharmaceutical market, primarily serving patients suffering from central nervous system (CNS) disorders. Asceneuron's business model revolves around research and development (R&D) of innovative small molecules that have the potential to halt and prevent neurodegeneration. The company generates revenue through partnerships, grants, and potential future sales of its therapeutic products. Asceneuron's R&D pipeline is designed to address significant gaps in current treatment options, aiming to improve patients' lives by providing effective solutions for complex brain diseases. The company actively participates in industry conferences and collaborates with leading experts to stay at the forefront of CNS therapeutic development.

Source: Dealroom company data

At a glance

Status
Operational
Employees
9
Open positions
None listed
Dealroom signal
62.5/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotechnology, Neurology, Genetics and genomics, Spinout, Biotech and Pharma, Longevity, DT and LS, science-based, Swiss DT Biotech
Business model
Manufacturing
Client focus
B2B

Funding history

5 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES COther financing Jul 2024 $100M $400M SR One · Johnson & Johnson Innovation · Sofinnova Partners · EQT Life Sciences ↗
GRANTOther financing May 2022 — — Michael J. Fox Foundation for Parkinson's Research ↗
Showing the latest 2 of 5 recorded eventsBook a demo for the full funding history →

Growth signals

Asceneuron website traffic

Latest recorded traffic for Asceneuron is 270 monthly website visits, down 79.2% over the last three months. Asceneuron's team declined 10% over the past year.

Latest monthly visits270 3-month web change-79.2% 1-year team growth-10%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Asceneuron in the Lausanne ecosystem

Live from Dealroom

The Asceneuron office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

11 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Seed1 investor entered at this stage

  • Michael J. Fox Foundation for Parkinson's Research

Series A5 investors entered at this stage

Series B and later4 investors entered at this stage

  • Novo Holdings
  • EQT Life Sciences
  • GSK
  • OrbiMed

Other known investors1 additional known investor

  • Merck KGaA
Team profiled 10 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇨🇭 Switzerland55.6%
🇺🇸 United States22.2%
🇳🇱 Netherlands11.1%
🇬🇧 United Kingdom11.1%
4 countries shown

See Asceneuron’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.